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Abstract
Background: Bone marrow (BM) produces hematopoietic and progenitor cells that contribute to distant organ
inflammation and repair. Chronic obstructive pulmonary disease (COPD) is characterized by defective lung repair.
Yet, BM composition has not been previously characterized in COPD patients.
Methods: In this prospective and controlled study, BM was obtained by sternum fine-needle aspiration in 35 COPD
patients and 25 healthy controls (10 smokers and 15 never-smokers). BM cell count and immunophenotype were
determined by microscopy and flow cytometry, respectively. Circulating inflammatory (C-reactive protein, IL-6, IL-8)
and repair markers (HGF, IGF, TGF-β, VEGF) were quantified by ELISA. Results were integrated by multi-level network
correlation analysis.
Results: We found that: (1) there were no major significant pair wise differences between COPD patients and
controls in the BM structural characteristics; (2) multi-level network analysis including patients and controls identifies
a relation between immunity, repair and lung function not previously described, that remains in the COPD network
but is absent in controls; and (3) this novel network identifies eosinophils as a potential mediator relating immunity
and repair, particularly in patients with emphysema.
Conclusions: Overall, these results suggest that BM is activated in COPD with impaired repair capacity in patients
with more emphysema and/or higher circulating eosinophils.
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Background
The human bone marrow (BM) produces hematopoietic
cells that contribute to the inflammatory response [1], as
well as hematopoietic stem cells (HSC; CD34+) and
endothelial progenitor cells (EPC; CD34+ CD133+ KDR
+) that can migrate to distant tissues, such as the lungs,
and modulate both the inflammatory response and tissue
repair [2–5].
The role of some repair markers and growth factors
have been studied in COPD patients or pre-clinical COPD
models. It has been described that human mesenchymal
stromal cells exert hepatocyte growth factor (HGF)
dependent cytoprotective effects in a human relevant
pre-clinical model of COPD [6]. Also, impaired vascular
endothelial growth factor (VEGF) signalling has been as-
sociated with emphysema in animal models [7]. Recently,
a possible novel role of insulin-like growth factor (IGF)
has been described. IGF participate in the control of air-
way epithelial cell differentiation and the bronchiolar air-
way epithelial repair kinetics regulation after injury in
various pulmonary diseases, such as asthma and COPD
[8]. Finally, the transforming growth factor-beta (TGF-β)
family regulates cell proliferation, differentiation, extracel-
lular matrix synthesis, and apoptosis. Attenuation of
TGF-β signalling leads to pulmonary emphysema in ani-
mal models [9] and has been shown to be decreased in
the bronchiolar epithelium in patients with stable COPD
compared with control smokers with normal lung func-
tion [10].
Chronic obstructive pulmonary disease (COPD) is char-
acterized by both pulmonary and systemic inflammation,
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as well as by defective lung repair [11]. Indirect evidence
supports the hypothesis that BM function in COPD is al-
tered, as suggested by the reduced number of
circulating-HSC and EPC in these patients [12], particu-
larly in those with more severe airflow limitation [13] and
low body mass index (BMI) values [14]. However, a recent
small study did not identify significant differences in BM
progenitor cell markers between 9 COPD patients and 9
age-matched, never-smoking controls [15]. Accordingly,
in the present study we sought to use a holistic approach
(network analysis [16]) to compare the characteristics of
BM (and circulatory inflammation and repair markers) in
a larger series of COPD patients and smoking and
never-smoking controls with normal spirometry. Further,
because patients with emphysema generally have severe
airflow limitation and low BMI values [16], we hypothe-
sized that differences would be magnified in these sub-
group of patients. Finally, given that high circulating
eosinophil levels (Eos), another BM-derived cell, seem to
relate to clinical outcomes in COPD [17, 18], we also con-
trasted COPD patients with less or ≥ 300 circulating Eos/
μL.
Methods
Study design and ethics
We included in this prospective and controlled study 35
clinically stable COPD patients defined by GOLD cri-
teria [11] and 25 healthy controls (10 current smokers
and 15 never smokers with normal spirometry) who re-
quired planned cardio-thoracic surgery for clinical rea-
sons (COPD and smoker controls had indication for
lung resection due to lung nodule or cancer by thoracic
surgery and never-smoker controls had indication for
valve replacement by cardiac surgery).
Lung function
Forced spirometry, static lung volumes and carbon mon-
oxide diffusing capacity (DLCO) were determined follow-
ing international recommendations, using Mediterranean
reference values [19, 20] in the pre-anaesthetic visit before
surgery.
Bone marrow harvesting and analysis
Sternum fine-needle (18G) BM aspiration (3–5 ml) was
performed by an expert haematologist in the surgical
theatre, once the patient was under general anaesthesia
and before the sternotomy. Fresh BM smears were used
for direct cell count (only in COPD patients). A 50 μl
BM sample was diluted 1:4 in 1× PBS (pH 7,4; PAA) and
analyzed using CELL-DYN Sapphire (Abbot, USA) to
determine cell types distribution. HSC and EPC were
isolated from fresh BM aspirates using a RosetteSep Kit
(STEMCELL Technologies Inc., Canada) following man-
ufacturer’s instructions to obtain a more representative
sample. Cells were quantified by flow cytometry on a
FACScan (Coulter Epics XL-MCL; Beckmann Coulter)
by the presence of antigens CD34 (BD Pharmingen, NJ,
USA), KDR (R&D Systems, Minneapolis, USA), CD133
(Miltenyi Biotec, Germany), c-kit, Ki67 (Abcam, Cam-
bridge, UK). Gates were set to detect CD34+ cells and to
evaluate co-expressions of CD34+ cells with CD 133,
KDR, c-kit and Ki67. At least 20.000 events were ac-
quired for each sample. Following previous publications
[2–4], EPCs were also identified by FACS as CD34+
CD133+ KDR+ cells. The remaining BM sample were
centrifuged at 1800 rpm/5 min/4 °C to separate cells
from plasma and the supernatant was stored (100 μl ali-
quots) at − 80 °C until cytokine analysis.
Circulating inflammatory and tissue repair markers
Circulating blood (10 ml) was collected in tubes with or
without EDTA by venipuncture before anaesthesia. Total
and differential leukocyte counts were determined auto-
matically (Sysmex K-4500, Toa Medical Electronics Co
Ltd., Kobe, Japan). Blood was allowed to clot and serum
was separated by centrifugation at 3000 rpm for 15 min
at 4 °C and stored at − 80 °C until analysis. The concen-
tration of IL-6 (Labclinics, Barcelona, Spain), IL-8 (Invi-
trogen, California, USA), VEGF (Ebioscience), TGF-β
(Ebioscience), IGF (R&D Systems) and HGF (Invitrogen)
in plasma (and BM supernatant) were determined by
ELISA. Assay sensitivities, as expressed by the manufac-
turer, were: 0.03 pg/ml for IL-6, < 100 fg/ml for IL-8,
7.9 pg/ml for VEGF, 8.6 pg/ml for TGF-β, 0.056 ng/mL
for IGF and 20 pg/ml for HGF. C-reactive protein (CRP)
concentration was determined by Nephelometry.
Data and network analysis
Results are expressed as mean ± standard deviation, or
median [interquartile range] values. ANOVA (or
Kruskall-Wallis test) and unpaired t-test (or Mann-Whitney
U-tests) were used to compare normally (and abnormally)
distributed variables. Bivariate correlations were tested with
Spearman test. Differences were considered statistically sig-
nificant at 2-tailed p < 0.05 and the stronger of these Spear-
man relationships (threshold p-value < 0.01) between clinical
and biological variables were plotted together as multi-level
networks by representing variables as nodes and correlations
between them as edges as previously described [21–23].
These correlation networks were constructed with custom R
scripts and Cytoscape [24]. The multi-level network includes
variables from multiple levels (or categories), including clin-
ical, lung function, BM and circulating blood information.
Each node in the network corresponds to a specific variable
(see names) whose colour denotes the level to which it be-
longs (see legends). Nodes are linked by edges only if their
Spearman correlation was statistically significant (p < 0.01),
either positively (continuous lines) or negatively (dashed
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lines). The thickness of the edge is proportional to the correl-
ation coefficient (Rho) (see legends). Grey shaded areas high-
light 5 isolated modules (or sub-networks) that are named
arbitrarily based on the assessment by the investigators of
the type of variables included in each of them. In order to
compare different biological effects, we built different net-
works comparing COPD and controls, COPD with DLCO<
60% or ≥ 60%, COPD with blood eosinophils< 300 or ≥ 300
cells/μL, and COPD with a smoking history< 45 or ≥
pack-years.
Results
Bivariate comparisons across groups
Table 1 presents the main demographic and clinical
characteristics of the three groups studied. By design,
smoking history and lung function values were different
between them. BMI was higher in never smokers (p <
0.05). COPD patients had moderate-severe airflow limi-
tation, gas trapping and reduced DLCO.
The percentages of cells expressing immune-phenotypic
(HSC (CD34+) and EPC (CD34+ CD133+ KDR+)) or pro-
liferation and differentiation markers (Ki67+, c-kit+) were
similar pair wisely across groups (Table 2). Likewise, we
did not find significant differences between groups in in-
flammatory or repair biomarkers, neither in BM or circu-
lating blood, with the exception of increased CRP levels in




We first built a multi-level correlation network (Fig. 1)
that included all participants (n = 60). The following ob-
servations are worth noting in Fig. 1: (#1) the Bone Mar-
row module has 11 nodes, all of them corresponding to
BM measurements; (#2) the Lung Function module is
the largest one (n = 13) and relates, as expected, FEV1,
DLCO and BMI. Interestingly, it also includes several
growth factors (HGF in BM as well as HGF, VEGF, IGF
in peripheral blood), repair factors (TGF-β) and the
percentatge of BM EPCs. Besides, circulating Eos relate
inversely to both FEV1 and DLCO; (#3) the Immunity-R-
epair module relates the percentage of BM lymphocytes,
B cells (CD19) and Eos with that of HSC (CD34); (#4)
the Blood module includes a well defined sub-network of
absolute counts of circulating cells, to some extend
equivalent to those found in #1 (Bone Marrow), which
included only BM markers; and, finally, (#5) the Mϕ
(Macrophage) module, relates the levels of BM metamye-
locytes and Monocytes/ Mϕ. All in all, these observa-
tions indicate the existence of a number of modules that
can be “expected” physiologically (#1, #4-#5), but high-
light that of some “unexpected” modules (#2 Lung func-
tion and #3 the Immunity-Repair module) that are really
multi-level and relate clinical, functional, BM and circu-
lating markers of relevance in the context of the present
analysis.
Comparison across groups: COPD vs. controls
Figure 2 presents the correlation networks determined
independently in COPD patients (n = 35), Smokers (n =
10) and Never-smokers (n = 15). It is important to note
from the outset that the different number of individuals
included in each network can modulate its structure,
since the possibility of identifying significant correlations
increases with sample size [25]. With this caveat in
mind, Fig. 2 shows greater number of inter-connected
nodes involved in the COPD network and that this net-
work incorporates lung function variables, BM and
blood markers of inflammation and repair that are not
observed in controls (Fig. 2). To address the potential
confounding effect of sample size differences, we in-
creased the sample size of the control network by mer-
ging smokers and never smokers with normal
spirometry (n = 25). Additional file 1: Figure S1 confirms
that the COPD network continues to be more intercon-
nected that that of merged controls, suggesting a higher
level of system activation. Of note, FEV1, DLCO and cir-
culating Eos are clearly related in COPD patients. Also,
to assess the potential confounder effect of differential
Table 1 Demographic and clinical characteristics (mean ± SD) of participants. Bolded italic text highlight variables with statistically
significant differences (p ≤ 0.05)
Never-smokers (n = 15) Smokers (n = 10) COPD (n = 35) P-value
Age, years 62.50 ± 16.69 63.95 ± 10.36 66.35 ± 8.10 0.35
BMI, kg/m2 33.00 ± 4.96 27.86 ± 4.36 27.05 ± 4.20 < 0.01
Pack years 0.00 ± 0.00 45.4 ± 22.82 51.0 ± 26.03 < 0.01
FEV1, % reference 105.61 ± 14.53 100.88 ± 14.01 64.26 ± 20.79 < 0.01
FEV1/FVC, % 79.29 ± 6.18 78.47 ± 5.29 53.84 ± 13.74 < 0.01
RV, % reference 112.8 ± 25.10 99.88 ± 23.69 172.41 ± 56.27 < 0.01
DLCO, % reference 91.21 ± 24.01 82.79 ± 13.90 60.79 ± 17.15 < 0.01
BMI Body mass index, FEV1 Forced expiratory volume in 1st second, FVC Forced vital capacity, RV Residual volume, DLCO Diffusing capacity of the lung for
carbon monoxide
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Table 2 Pair wise comparison of BM and circulating inflammatory and repair markers (median [IQR] or mean ± SD) in the three
groups studied. Bolded italic text highlights variables with statistically significant differences (p ≤ 0.05)
Never-smokers (n = 15) Smokers (n = 10) COPD (n = 35) ANOVA (or KW) P Value
BM CHARACTERIZATION
Immunophenotype
CD3% 5.00 [5.00–6.00] 5.50 [3.30–7.00] 6.00 [4.00–9.50] 0.59
CD5% 5.00 [5.00–6.00] 5.00 [3.00–7.00] 6.00 [4.30–9.80] 0.40
CD7% 7.00 [5.30–8.00] 6.00 [4.00–9.00] 6.00 [5.00–9.80] 0.78
CD10% 20.00 [13.00–26.00] 19.00 [15.00–28.50] 19.50 [15.80–25.80] 0.79
CD19 + % 3.00 [2.00–4.50] 3.00 [2.00–6.30] 3.00 [2.00–4.00] 0.57
CD19 + CD10 + % 2.00 [1.30–3.00] 0.50[0.50–2.50] 2.00 [1.00–2.00] 0.62
CD33% 76.00 [68.50–80.00] 68.50 [61.30–79.00] 71.50 [65.00–80.00] 0.47
CD13% 34.50 [30.00–39.50] 30.00 [20.00–40.00] 30.00 [25.00–33.00] 0.43
CD14% 2.00 [1.30–3.80] 3.00 [2.00–4.00] 3.00 [2.00–4.00] 0.31
CD15% 70.00 [57.50–75.00] 62.50 [56.30–73.80] 65.00 [60.00–70.00] 0.70
CD117% 2.00 [1.50–2.00] 2.00 [2.00–2.80] 2.00 [2.00–2.80] 0.40
CD34% 1.00 [1.00–2.00] 2.00 [1.00–2.80] 1.00 [1.00–2.00] 0.50
DR% 8.00 [4.50–11.00] 9.50 [7.30–10.00] 8.00 [7.503–10.00] 0.81
CD4% 3.00 [3.00–3.00] 3.00 [2.00–3.40] 3.50 [3.00–4.80] 0.24
CD8% 2.00 [2.00–3.00] 2.00 [1.30–4.00] 3.00 [2.00–4.00] 0.66
CD56% 1.00 [1.00–1.80] 1.00 [1.00–2.00] 1.00 [1.00–1.00] 0.83
sCD64% 3.00 [1.50–5.00] 3.00 [2.00–4.00] 3.00 [2.00–4.00] 0.88
Progenitor cell surface markers
CD34
% 7.38 [2.28–16.23] 13.44 [10.50–18.02] 14.50 [9.83–24.10] 0.07
MFI 164.60 [110.50–202.80] 118.03 [54.99–335.73] 92.65 [65.85–113.10] 0.09
CD 34 + c-kit+
% 76.40 [67.00–85.40] 65.98 [57.88–79.71] 81.90 [66.80–84.70] 0.41
MFI 24.70 [19.60–39.65] 19.95 [15.85–70.73] 38.10 [24.80–55.40] 0.36
CD 34 + Ki67+
% 69.40 [30.30–77.40] 83.30 [59.99–97.64] 96.80 [73.30–97.90] 0.72
MFI 31.80 [22.35–52.90] 28.00 [21.75–70.65] 50.30 [43.30–74.30] 0.32
CD34 + 133 + KDR+
% 1.10 [0.00–3.05] 1.23 [0.18–1.80] 4.35 [1.58–7.73] 0.51
MFI 78.00 [37.93–127.15] 112.40 [74.48–134.73] 49.25 [40.10–120.60] 0.33
INFLAMMATORY AND REPAIR MARKERS
BM Supernatant
IL6 pg/ml 12.20 [1.30–23.00] 13.06 [1.65–27.39] 9.80 [7.60–24.90] 0.06
IL-8 pg/ml 6.50 [3.90–10.70] 7.10 [3.00–8.70] 3.60 [2.40–10-90] 0.48
HGF pg/ml 2854.07 [646.71–22,718.86] 1290.97 [909.37–9284.43] 1689.59 [692.43–2466.46] 0.63
Circulating blood
Leucocytes ×10^9/L 7.67 ± 3.43 8.41 ± 2.45 7.41 ± 1.88 0.52
Neutrophils % 55.07 ± 18.58* 71.98 ± 11.92 61.69 ± 11.85 0.02
Eos % 2.13 ± 1.77 1.46 ± 1.19 3.14 ± 1.65† 0.01
CRP mg/dl 1.62 ± 2.05 0.90 ± 2.19 5.65 ± 12.57‡ 0.02
IL-6 pg/ml 0.10 [0.10–0.10] 0.10 [0.00–0.10] 0.10 [0.1–0.20] 0.14
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sample size on network density comparisons, we per-
formed patients sub-sampling analysis in COPD or Con-
trols. For each group, we averaged correlations
coefficients and p-values of n = 1000 random subgroups
of patients of n = 25, and observed that the difference in
density is not due to differential sample size.
COPD phenotypes: Emphysema and circulating eosinophils
To get further insight into the relationship between em-
physema, circulating Eos [26, 27] and BM response in
COPD, as established a priori in the analysis plan, we first
compared the results obtained in COPD patients with
DLCO values higher or lower than 60% of reference, a
well-established surrogate marker of emphysema [16]. As
expected [16], lung function was worse in the latter pa-
tients (Additional file 3: Table S1). In patients with
DLCO≥60% ref., bone marrow cellularity was enriched in
white blood cells and segmented neutrophils (Additional
file 3: Table S1). By contrast, the network was less struc-
tured in patients with DLCO< 60% ref., suggesting less
network resilience [21] and impaired repair capacity in pa-
tients with emphysema (Additional file 2: Figure S2). Of
Table 2 Pair wise comparison of BM and circulating inflammatory and repair markers (median [IQR] or mean ± SD) in the three
groups studied. Bolded italic text highlights variables with statistically significant differences (p ≤ 0.05) (Continued)
Never-smokers (n = 15) Smokers (n = 10) COPD (n = 35) ANOVA (or KW) P Value
IL-8 pg/ml 1.40 [0.90–2.50] 2.80 [1.30–5.90] 2.30 [1.5–3.10] 0.82
IL Interleukin, HCG Hepatocyte growth factor, MFI Mean fluorescence intensity; *P-value< 0.05 compared to never-smoking controls; †P-value< 0.05 compared to
smoking controls; ‡P-value< 0.05 compared to never-smoking and smoking controls
Fig. 1 Multi-level correlation network that includes all participants in the study. For further explanations, see text. Abbreviations: Abs: absolute
count; HSC: Hematopoietic stem cells; EPC: Endothelial progenitor cells; TNF: Tumour necrosis factor; TGF-ß: Transforming growth factor beta;
VEGF: Vascular endothelial growth factor; IGF: Insulin-like growth factor; IL: Interleukin; RBC: Red blood cells; WBC: White blood cells; Lympho:
Lymphocytes; Segmented: segmented neutrophils; E. Polychrom: Polychromatic erythroblast; E. Basophils: Basophils erythroblast; E. Ortochrom:
Ortochromatic erythroblast; T cells: T lymphocytes; B cells: B lymphocytes; Plasmatic: Plasmatic cells; Hb: haemoglobin; Eos: Eosinophils; Mono/
Macro: Monocyte/Macrophages; MFI: Mean fluorescence intensity; Mono: Monocyte; Neutro: Neutrophil; Bas: Basophil; Mφ: Macrophage; FEV1:
forced expiratory volume in 1st second; DLCO: Diffusing capacity of the lung for carbon monoxide; BMI: body mass index
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note, circulating Eos were higher in these latter patients
(Additional file 3: Table S1).
Secondly, we compared the network characteristics of
COPD patients with less or ≥ 300 Eos/μL (Additional file 3:
Table S2). The latter patients showed worse lung function
and a reduced proportion of BM plasma cells and CD34+
c-kit+, as well as circulating neutrophils. The remaining
BM and circulatory markers were similar in both groups.
Additional file 4: Figure S3 shows that the multilevel correl-
ation network was less well structured in patients with
≥300 circulating Eos/μL, suggesting again less resilience of
the system [21].
Discussion
The major novel findings of this study were that: [1] there
were no major significant individual pair wise differences
between COPD patients, smokers and never-smoker
controls in the composition of immune-phenotypic, prolif-
eration and differentiation, inflammatory or repair markers,
neither in BM or circulating blood; [2] the novel multi-level
correlation network approach used here identified (in all
participants) a relation between immunity, repair and lung
function not previously described; [3] network analysis also
showed a greater number of interconnected nodes in
COPD patients than in controls, with the presence of im-
munity and repair nodes not include in the network of con-
trols; and [4] in COPD eosinophils appear as a possible
central regulatory cell relating immunity and repair with
lung function abnormalities and emphysema.
Previous studies
Some previous reports have shown reduced BM-derived
circulating progenitors (CD34+ cells) in patients with
COPD, particularly in those with more severe airflow
Fig. 2 Multi-level correlation network calculated in never-smokers, smokers and COPD patients separately. For further explanations, see text.
Abbreviations: Abs: absolute count; HSC: Hematopoietic stem cells, HSC prolif: Hematopoietic stem cells with a proliferative marker; TNF: Tumour
necrosis factor; TNF R80: Tumour necrosis factor receptor p80; IL: Interleukin; RBC: Red blood cells; WBC: White blood cells; Lympho: Lymphocytes;
Segmented: segmented neutrophils; E. Polychrom: Polychromatic erythroblast; E. Basophils: Basophils erythroblast; E. Ortochrom: Ortochromatic
erythroblast; B cells: B lymphocytes, Eos: Eosinophils; Mono/Macro: Monocyte/Macrophages; MFI: Mean fluorescence intensity; Neutro: Neutrophil;
Bas: Basophil; FEV1: forced expiratory volume in 1st second, DLCO: Diffusing capacity of the lung for carbon monoxide, BMI: body mass index
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limitation, arterial hypoxemia and low-BMI [12, 14]. On
the other, Broekman et al. recently described that the
immune-phenotype, growth, differentiation and migra-
tion capacity of BM progenitor cells were not different
between 9 COPD patients and 9 age-matched,
never-smoking, controls [15]. The results of our pair
wise analysis (Table 1) are in keeping with this latter re-
port. However, our study extends all these previous stud-
ies by including a larger number of patients and controls
and, specially, by using, for the first time, multilevel net-
work analysis to get a holistic understanding of the sys-
tem, both at the BM, circulating blood and physiologic
levels.
Interpretation of results
Despite that, by and large, we did not find significant
pair wise differences between groups in the different
immune-phenotypic, proliferation and differentiation, in-
flammatory or repair markers, neither in BM or circulat-
ing blood (Table 1), the use of multi-level correlation
network analysis provided several observations of inter-
ests. Firstly, it identifies a module in which B-cells, pro-
genitor cells (CD34+) and eosinophils interact in the
whole population, as well as a second module that re-
lates lung function parameters with immunity and repair
nodes. Secondly, the network was more interconnected,
hence more complex and developed, in COPD patients
than in controls (Fig. 2 and Additional file 1: Figure S1),
suggesting chronic system activation in COPD. The dif-
ference might, however, be due to the higher cumulated
smoking history of COPD patients, as we have observed
a denser network when comparing networks of patients
with Pack-Years≥45 versus Pack-Years< 45 (Additional
file 5: Figure S4).Thirdly, the COPD correlation network
was more fragmented in those patients with emphysema
(DLCO< 60% reference) or ≥ 300 circulating Eos/μL, in-
dicating reduced system resilience [21] and potentially
impaired repair capacity. This is consistent with the ac-
cepted pathogenesis of emphysema [28, 29] but high-
lights a novel patho-biological effect of eosinophils in
the lung maintenance program. In fact, supporting this
hypothesis and in keeping with previous studies [30, 31],
we found that COPD patients with ≥300 Eos/μL had
worse lung function and less BM HSCs (Table S2), sug-
gesting deficient BM repair response. In support of this
hypothesis is the recent observation in the COPDgene
cohort of a relation between biomarkers of extracellular
matrix turnover, emphysema and eosinophilic-bronchitis
in patients with COPD [27]. Moreover, other studies
have found involvement of eosinophils in colonic inflam-
mation and repair [26]. The finding of eosinophils as
cells that are present in almost all the networks being
one of the most connected hubs in each network and
also the different number of compartments in which it
was involved (as clinical variables, blood cytokines, bone
marrow surface markers) made us to consider the role
of eosinophil as a possible regulatory cell.
Finally, we did not find differences in the bivariate ana-
lysis between different growth factors but the network ana-
lysis showed relationships among HGF, VEGF, TGF, EPCs,
eosinophils and lung function parameters. It has been re-
cently described that human mesenchymal stromal cells
exert HGF dependent cytoprotective effects in a human
relevant pre-clinical model of COPD [6], that is consistent
with the role of HGF in the network connected with
DLCO, FEV1 and EPC. Moreover, impaired VEGF signaling
has been associated with emphysema in animal models [7]
and our network shows an inverse correlation with EPC
which could be explained as a consequence of the impaired
repair mechanisms in these patients.
Strengths and limitations
The use, for the first time, of network analysis to under-
stand the BM system in a large cohort of COPD patients
and controls is a clear strength of our study. It also has,
however, some potential limitations that deserve comment.
First, because COPD patients (and controls) required
cardio-thoracic surgery for clinical reasons (with different
indication for cases and controls), results may not be auto-
matically generalised. Second, as discussed above, we stud-
ied a higher number of COPD patients than controls, and
this may influence the structure of correlation networks
[25]. To address this, we increased the number of controls
by merging smokers and never smokers, and yet found
similar results. However, we still could not correct for the
effect of active smoking due to the sample size. Third, net-
work density is also directly proportional to the threshold
chosen for statistical significance, the lower the p value, the
higher network density. To get an appropriate signal to
noise balance, as others have done before [16, 21], we estab-
lished an arbitrary p threshold value of less than 0.01, so
weaker relationships were not included in the network.
Fourth, although the data point to eosinophil as a possible
mediator of the immune and repair response, especially in
patients with emphysema, the authors cannot exclude the
presence of other co-mediators and further studies are
needed to demonstrate the role of these cells in the repair
process of the lung. In keeping with this, due to the sample
size we could not explore the effects of inhaled corticoste-
roids, that some of these patients were receiving, on the
BM characteristics. Finally, we studied only one source of
stem cells, namely the BM, while there are other organs
also able to produce these cells, such as the spleen or even
the lung themselves [32].
Conclusions
These results suggest that BM seems to be chronically
activated in COPD, despite there are not differences in
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the baseline structure and function between COPD and
controls. Moreover, the resilience and repair capacity of
the system can be impaired in patients with more em-
physema and/or higher circulating Eos.
Additional files
Additional file 1: Figure S1. Multi-level correlation network of COPD pa-
tients and merged controls (smokers and non-smokers with normal spir-
ometry). For further explanations, see text. Abbreviations: Abs: absolute
count; HSC: Hematopoietic stem cells, TNF R80: Tumour necrosis factor
receptor p80; HGF: Hepatocyte growth factor; VEGF: Vascular endothelial
growth factor, IL: Interleukin; RBC: Red blood cells; WBC: White blood
cells; Lympho: Lymphocytes; Segmented: segmented neutrophils; E. Poly-
chrom: Polychromatic erythroblast; E. Basophils: Basophils erythroblast; E.
Ortochrom: Ortochromatic erythroblast; B cells: B lymphocytes; Hb:
haemoglobin, Eos: Eosinophils; Mono/Macro: Monocyte/Macrophages;
MFI: Mean fluorescence intensity; Neutro: Neutrophil; FEV1: forced expira-
tory volume in 1st second; DLCO: Diffusing capacity of the lung for car-
bon monoxide, BMI: body mass index. (JPG 51 kb)
Additional file 2: Figure S2. Multi-level correlation network of COPD
patients with DLCO ≥60% or <60%. For further explanations, see text.
Abbreviations: Abs: absolute count; HSC: Hematopoietic stem cells; EPC:
Endothelial progenitor cells; TNF R80: Tumour necrosis factor receptor
p80; TGF-ß: Transforming growth factor beta; HGF: Hepatocyte growth
factor; VEGF: Vascular endothelial growth factor; IGF: Insulin-like growth
factor; RBC: Red blood cells; Lympho: Lymphocytes; Segmented: segmented
neutrophils; E. Polychrom: Polychromatic erythroblast; E. Ortochrom: Orto-
chromatic erythroblast; B cells: B lymphocytes; Plasmatic: Plasmatic cells; Hb:
haemoglobin; Eos: Eosinophils; Mono/Macro: Monocyte/Macrophages; MFI:
Mean fluorescence intensity; Mono: Monocyte; Neutro: Neutrophil; FEV1:
forced expiratory volume in 1st second; DLCO: Diffusing capacity of the lung
for carbon monoxide; BMI: body mass index. (JPG 60 kb)
Additional file 3: Table S1. Bone marrow characterization,
inflammatory and repair markers (mean±SD or median [IQR]) in COPD
patients with DLCO higher or lower than 60% of reference. Bolded italic
text highlight variables with statistically significant differences ( p≤0.05).
Table S2. Bone marrow characterization, inflammatory and repair
markers (mean±SD or median [IQR]) in COPD patients with peripheral
blood eosinophil counts <300 or ≥300/μL. Bolded italic text highlight
variables with statistically significant differences (p≤0.05). (DOCX 42 kb)
Additional file 4: Figure S3. Multi-level correlation network of COPD
patients with peripheral blood eosinophil counts <300/μL or ≥300/μL.
For further explanations, see text. Abbreviations: Abs: absolute count;
HSC: Hematopoietic stem cells; EPC: Endothelial progenitor cells; TNF R80:
Tumour necrosis factor receptor p80; VEGF: Vascular endothelial growth
factor; RBC: Red blood cells; WBC: White blood cells; Lympho: Lympho-
cytes; Segmented: segmented neutrophils; E. Ortochrom: Ortochromatic
erythroblast; T cells: T lymphocytes; Plasmatic: Plasmatic cells; Mono/
Macro: Monocyte/Macrophages; Mono: Monocyte; Neutro: Neutrophil;
FEV1: forced expiratory volume in 1st second; DLCO: Diffusing capacity of
the lung for carbon monoxide; BMI: body mass index. (JPG 53 kb)
Additional file 5: Figure S4. Multi-level correlation network of COPD
patients with smoking history <45 pack-years or ≥45 pack-years. For further
explanations, see text. Abbreviations: Abs: absolute count; HSC: Hematopoietic
stem cells; TNF: Tumour necrosis factor; VEGF: Vascular endothelial growth fac-
tor; HGF: Hepatocyte growth factor; IL: Interleukin; RBC: Red blood cells; WBC:
White blood cells; Lympho: Lymphocytes; B cells: B lymphocytes; T cells: T lym-
phocytes; Mono: Monocyte; Neutro: Neutrophil; Segmented: segmented neu-
trophils; Eos: Eosinophils; E. Ortochrom: Ortochromatic erythroblast; E.
Polychrom: Polychromatic erythroblast; FEV1: forced expiratory volume in 1szt
second; DLCO: Diffusing capacity of the lung for carbon monoxide; BMI: body
mass index. (JPG 59 kb)
Abbreviations
BM: Bone marrow; BMI: Body mass index; COPD: Chronic obstructive
pulmonary disease; CRP: C-reactive protein; DLCO: Carbon monoxide
diffusing capacity; ELISA: Enzyme-Linked Immunosorbent Assay;
Eos: Eosinophil; EPC: Endothelial progenitor cells; FEV1: Forced expiratory
volume in the first second; HGF: Hepatocyte growth factor;
HSC: Hematopoietic stem cells; IGF: Insulin-like growth factor; IL: Interleukin;
Mφ: Macrophage; TGF-β: Transforming growth factor beta; VEGF: Vascular
endothelial growth factor
Acknowledgements
Authors thank the participants in this study for their willingness to contribute
to medical research. Authors also thank Dr. Laura Vidal, and all the Cardio-
thoracic surgery team of Hospital Universitari Son Espases (Palma de Ma-
llorca, Spain) for their help during BM aspiration.
Funding
This study has been supported, in part, by Fondo de Investigación Sanitaria,
Instituto Carlos III (PI08/0780), CIBERES and beca SEPAR.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
N.T-P and BG.C designed the study, had full access to all of the data in the
study and take responsibility for the integrity of the data and the accuracy of
the data analysis. N.T-P. served as principal author. N.T, G.N, A.J, A.I, MA.D, J.I,
A.R, S.S, R.F, O.G, A.A and BG.C contributed to data collection and
interpretation; N.T-P performed the statistical analyses; finally N.T-P, BG.C, and
A.A drafted the first manuscript, and finally approved this submission.
Ethics approval and consent to participate
The study was approved by the Ethics Committee of the Balearic Islands (CI-




Dr. Agusti reports, outside the submitted work, grants and personal fees
from Astra-Zeneca, GSK and Menarini, grants from MSD and personal fees
from Novartis, TEVA and Chiesi. Dr. Cosio reports personal fees from AstraZe-
neca, Rovi and Esteve, grants from Boehringer and grants and personal fees
from Novartis, Chiesi and Menarini, all of them outside the submitted work.
All the other authors have no conflict of interest to declare.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III,
Madrid, Spain. 2Department of Respiratory Medicine, Hospital Universitari Son
Espases-IdISBa, Valldemossa 79, 07010 Palma de Mallorca, Spain. 3Institut
d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
4Department of Hematology, Hospital Universitari Son Espases-IdISBa,
Mallorca, Spain. 5Department of Immunology, Hospital Universitari Son
Espases-IdISBa, Mallorca, Spain. 6Department of Thoracic Surgery, Hospital
Universitari Son Espases-IdISBa, Mallorca, Spain. 7Department of Medicine,
Universitat de Barcelona, Barcelona, Spain. 8Respiratory Institute, Hospital
Clinic, University of Barcelona, Barcelona, Spain.
Received: 22 February 2018 Accepted: 8 June 2018
References
1. Anthony B, Link DC. Regulation of hematopoietic stem cells by bone
marrow stromal cells. Trends Immunol. 2014;35:32–7.
2. Osumi N, Shinohara H, Numayama-Tsuruta K, Maekawa M. Concise review:
Pax6 transcription factor contributes to both embryonic and adult
neurogenesis as a multifunctional regulator. Stem Cells. 2008;26:1663–72.
3. Kim E-K, Lee J-H, Jeong H-C, Oh D, Hwang S-G, Cho Y-W, Lee S-J, Oh Y-M,
AS-D L. Impaired Colony-forming capacity of circulating endothelial
Toledo-Pons et al. Respiratory Research  (2018) 19:118 Page 8 of 9
progenitor cells in patients with emphysema. Tohoku J Exp Med. 2012;227:
321–31.
4. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for
organ vascularization and regeneration. Nat Med. 2003;9(6):702-12
5. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin
DJ, Witte L, Moore MAS, Rafii S. Expression of VEGFR-2 and AC133 by
circulating human CD34 (+) cells identifies a population of functional
endothelial precursors. Blood. 2000;95(3):952-8.
6. Kennelly H, Mahon BP, English K. Human mesenchymal stromal cells exert
HGF dependent cytoprotective effects in a human relevant pre-clinical
model of COPD. Sci Rep. 2016;6:38207.
7. Bakakos P, Patentalakis G, Papi A. Vascular biomarkers in asthma and COPD.
Curr Top Med Chem. 2016;16:1599–609.
8. López IP, Piñeiro-Hermida S, Pais RS, Torrens R, Hoeflich A, Pichel JG.
Involvement of Igf1r in bronchiolar epithelial regeneration: role during
repair kinetics after selective club cell ablation. PLoS One. 2016;11:1–32.
9. Gao C, Maeno T, Ota F, Ueno M, Korekane H, Takamatsu S, Shirato K,
Matsumoto A, Kobayashi S, Yoshida K, Kitazume S, Ohtsubo K, Betsuyaku T,
Taniguchi N. Sensitivity of heterozygous alpha1,6-fucosyltransferase knock-
out mice to cigarette smoke-induced emphysema: implication of aberrant
transforming growth factor-beta signaling and matrix metalloproteinase
gene expression. J Biol Chem. 2012;287:16699–708.
10. Di Stefano A, Sangiorgi C, Gnemmi I, Casolari P, Brun P, Ricciardolo FLM,
Contoli M, Papi A, Maniscalco P, Ruggeri P, Girbino G, Cappello F, Pavlides S,
Guo Y, Chung KF, Barnes PJ, Adcock IM, Balbi B, Caramori G. TGF-β signaling
pathways in different compartments of the lower Airways of Patients with
Stable COPD. Chest. 2017;153:851–62.
11. From the Global Strategy for the Diagnosis, Management and Prevention of
COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017.
Available from: http://goldcopd.org.
12. Palange P, Testa U, Huertas A, Calabrò L, Antonucci R, Petrucci E, Pelosi E,
Pasquini L, Satta A, Morici G, Vignola MA, Bonsignore MR. Circulating
haemopoietic and endothelial progenitor cells are decreased in COPD. Eur
Respir J. 2006;27:529–41.
13. Janssen WJ, Yunt ZX, Muldrow A, Kearns MT, Kloepfer A, Barthel L, Bratton
DL, Bowler RP, Henson PM. Circulating hematopoietic progenitor cells are
decreased in COPD. COPD. 2014;11:277–89.
14. Huertas A, Testa U, Riccioni R, Petrucci E, Riti V, Savi D, Serra P, Bonsignore
MR, Palange P. Bone marrow-derived progenitors are greatly reduced in
patients with severe COPD and low-BMI. Respir Physiol Neurobiol. 2010;170:
23–31.
15. Broekman W, Roelofs H, Zarcone MC, Taube C, Stolk J, Hiemstra PS.
Functional characterisation of bone marrow-derived mesenchymal stromal
cells from COPD patients. ERJ open Res. 2016;2:1–10.
16. Faner R, Cruz T, Casserras T, Lopez-Giraldo A, Noell G, Coca I, Tal-Singer R,
Miller B, Rodriguez-Roisin R, Spira A, Kalko SG, Agusti A. Network analysis of
lung transcriptomics reveals a distinct B-cell signature in emphysema. Am J
Respir Crit Care Med. 2016;193:1242–53.
17. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M,
Haldar K, Kebadze T, Duvoix A, Lindblad K, Patel H, Rugman P, Dodson P,
Jenkins M, Saunders M, Newbold P, Green RH, Venge P, Lomas DA, Barer
MR, Johnston SL, Pavord ID, Brightling CE. Acute exacerbations of chronic
obstructive pulmonary disease: identification of biologic clusters and their
biomarkers. Am J Respir Crit Care Med. 2011;184:662–71.
18. Cosio BG, Soriano JB, López-Campos JL, Calle-Rubio M, Soler-Cataluna JJ,
De-Torres JP, Marín JM, Martínez-Gonzalez C, De Lucas P, Mir I, Peces-Barba
G, Feu-Collado N, Solanes I, Alfageme I, Casanova C. Defining the asthma-
COPD overlap syndrome in a COPD cohort. Chest. 2016;149:45–52.
19. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R,
Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC,
MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G,
Wanger J. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.
20. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, Brusasco
V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J,
Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger
J. Standardisation of the single-breath determination of carbon monoxide
uptake in the lung. Eur Respir J. 2005;26:720–35.
21. Noell G, Cosío BG, Faner R, Monsó E, Peces-Barba G, de Diego A, Esteban C,
Gea J, Rodriguez-Roisin R, Garcia-Nuñez M, Pozo-Rodriguez F, Kalko SG,
Agustí A. Multi-level differential network analysis of COPD exacerbations. Eur
Respir J. 2017;50:1700075.
22. Barabasi A-L, Gulbahce N, Loscalzo J. Network medicine: a network-based
approach to human disease. Nat Rev Genet. 2011;12:56–68.
23. Diez D, Agusti A, Wheelock CE. Network analysis in the investigation of
chronic respiratory diseases. From basics to application. Am J Respir Crit
Care Med. 2014;190:981–8.
24. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N,
Schwikowski B, Ideker T. Cytoscape: a software environment for integrated
models of biomolecular interaction networks. Genome Res. 2003;13:2498–
504.
25. Goertzen JR, Cribbie RA. Detecting a lack of association: an equivalence
testing approach. Br J Math Stat Psychol. 2010;63:527–37.
26. Hadar R, Itay M, Michal I, Metsada P-C, Thomas V, Johannes R, Ariel M.
Transcriptome profiling of mouse colonic eosinophils reveals a key role for
eosinophils in the induction of s100a8 and s100a9 in mucosal healing. Sci
Rep. 2017;7:7117.
27. Bihlet AR, Karsdal MA, Sand JMB, Leeming DJ, Roberts M, White W, Bowler
R. Biomarkers of extracellular matrix turnover are associated with
emphysema and eosinophilic-bronchitis in COPD. Respir Res. 2017;18:22.
28. Lam AP, Gottardi CJ, Tuder R. Regenerative pathways and emphysema: a
new paradigm? Am J Respir Crit Care Med. 2011;183:688–90.
29. Tuder RM, Yoshida T, Fijalkowka I, Biswal S, Petrache I. Role of lung
maintenance program in the heterogeneity of lung destruction in
emphysema. Proc Am Thorac Soc. 2006;3:673–9.
30. Rogliani P, Puxeddu E, Ciaprini C, Ora J, Onorato A, Pezzuto G, Calzetta L,
Cazzola M. The time course of pulmonary function tests in COPD patients
with different levels of blood eosinophils. Biomed Res Int. 2016;2016
31. Queiroz CF, Lemos ACM, Bastos M de LS, Neves MCLC, Camelier AA,
Carvalho NB, de CEM. Inflammatory and immunological profiles in patients
with COPD: relationship with FEV 1 reversibility. J Bras Pneumol. 2016;42:
241–7.
32. Lefrançais E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM,
Thornton EE, Headley MB, David T, Coughlin SR, Krummel MF, Leavitt AD,
Passegué E, Looney MR. The lung is a site of platelet biogenesis and a
reservoir for haematopoietic progenitors. Nature. 2017;544:105–9.
Toledo-Pons et al. Respiratory Research  (2018) 19:118 Page 9 of 9
